Skip to main content
Premium Trial:

Request an Annual Quote

Roche, PerkinElmer Partner on NimbleGen CGX Sales

NEW YORK (GenomeWeb News) – PerkinElmer will sell, service, and provide support for Roche's NimbleGen CGX microarray workflow for most countries outside the US under a supply agreement deal announced today by the two companies.

Roche will continue to sell the workflow in the US and other select markets under the terms of the deal, which takes effect in January.

The NimbleGen CGX array workflow is for the discovery and anlaysis of copy number variations associated with constitutional disorders for the cytogenetics research market and consists of NimbleGen CGX microarrays, reagent kits, the NimbleGen Hybridization Systems, and software for data analysis from Signature Genomics, which PerkinElmer acquired last year.

The NimbleGen CGX array design was developed by Signature Genomics based on an analysis of more than 50,000 cytogenteic samples "to ensure appropriate coverage of the cytogenetically relevant regions," Roche and PerkinElmer said.

Financial and other terms of the deal were not disclosed.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.